All In Biotech

Drug Trial Radar · NCT03976843

Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer

A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

175

Actual

Start

Dec 4, 2019

Primary completion

Nov 19, 2027

Study completion Nov 19, 2027

Sponsor

Sponsor type
NIH
Collaborators
Lantheus
First posted
Jun 6, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Background: People with prostate cancer usually have their cancer imaged with a CT scan and bone scan. They then have their prostate gland removed. Researchers want to test a scan that might predict if prostate cancer will return after this surgery. Objective: To test if a PET/CT scan before the prostate gland is removed can predict if prostate cancer will return. Also, to test if this approach is better or worse than the usual approach for prostate cancer. Eligibility: Men ages 18 and older with prostate cancer that appears to be contained within the prostate but is at risk of having spread Design: Participants will be screened with: * Medical history * Blood tests * CT and MRI scans: Participants will lie in a machine. The machine will take pictures of the body. * Bone scan Participants will have a radiotracer injected into a vein. They will have a PET/CT scan of their whole body 60-90 minutes later. During the scan, they will lie on their back and stay still. Within 60 days after the scan, participants will have surgery. This will remove the prostate gland and lymph nodes around it. Some tissue will be used for genetic testing. If the PET/CT scan suggests the cancer has spread, participants may need to have another biopsy within 60 days after the scan. After surgery, participants will have follow-up visits for 5 years. They will have 5 visits the first year and 2 the second. Then they will have visits once a year. If participants cancer returns, they will have repeat PET/CT scans.

Conditions

  • Prostate Cancer

Interventions

  • 18F-DCFPyLDrug

    18F-labeled agent that is a high affinity small molecule inhibitor of PSMA to detect prostate cancer via PET imaging

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. progression free survivalTime frame: 6 weeks, 3,6,9,12, and 18 months, 2,3, and 4 years

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Tulane University

    New Orleans, Louisiana

  • Johns Hopkins University

    Baltimore, Maryland

  • National Institutes of Health Clinical Center

    Bethesda, Maryland

  • Brigham and Women s Hospital

    Boston, Massachusetts

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.